MedPiper Technologies vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru Diagnostics-as-a-Service API connecting 10,000+ India labs for telehealth and insurers; YC W20 $3.28M at 91% YoY growth enabling digital health platforms to embed diagnostics without logistics.
About
MedPiper Technologies is a Bengaluru-based Diagnostics-as-a-Service (DaaS) platform — India's first comprehensive diagnostic infrastructure API — enabling insurers, health plans, telehealth providers, and healthcare organizations to embed diagnostic services (lab tests, radiology, home sample collection) into their digital health workflows through a single white-label integration. Founded in 2020 and backed by Y Combinator (W20) with $3.28 million raised, MedPiper generates ₹5.57 crore (approximately $670,000 USD) in annual revenue with 91% year-over-year growth, serving the digital health ecosystem as the infrastructure layer that connects healthcare platforms to India's fragmented diagnostic laboratory network.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.